Please assess the completion status of the following clinical trial:

Trial Title: Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients receiving allogeneic peripheral blood stem cell transplant from either a related or unrelated donor at Washington University Medical Center.~* An initial episode of CMV viremia.~* At the time of randomization:~  * ANC greater than or equal to 1000~ * Age greater than or equal to 18~ * Adequate renal function with creatinine clearance greater than 10 ml/min~ * Total bilirubin less than or equal to 3.0~Exclusion Criteria:~* Current GI graft versus host disease grade III-IV~* Development of CMV disease prior to or at the time of the first detection of CMV viremia by PCR~* Uncontrolled emesis or diarrhea (greater than or equal to 4 episodes per day) for 2 consecutive days~* Pregnant or nursing female patient~* Known hypersensitivity to ganciclovir

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): IV ganciclovir (5mg/kg every 12 hours for 7 days followed by 5mg/kg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 5mg/kg every 24 hours for a total of 21 total days of therapy. If CMV viral load \>5000/ml but less than index viral load after 14 days then 5mg/kg every 24 hours for a total of 28 total days of therapy. If CMV viral load \>= index viral load after 14 days then 5mg/kg every 12 hours for 7 days. If repeat CMV viral load is \<= the previous CMV viral load then 5mg/kg every 12 hours for an additional 7 days.
- Group B (Type: EXPERIMENTAL): PO valganciclovir (900 mg every 12 hours for 7 days followed by 900 mg every 24 hours for 7 days. If CMV viral load \<5000 copies/ml after 14 days then 900 mg every day until 21 total days of therapy. If CMV viral load \>5000 copies/ml after 14 days but less than the index viral load then 900 mg every day until 28 total days of therapy. If CMV viral load \>= the index viral load 900 mg every 12 hours for 7 days, if CMV viral load \<= to previous viral load then 900 mg every 12 hours for another 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).